Grünenthal Completes Phase I Trial for First-in-Class NOP Agonist, Plans Phase II in Acute Pain
Key Insights
Grünenthal successfully completed a Phase I trial of its proprietary NOP agonist in 113 healthy participants, demonstrating safety and tolerability with no dose-dependent adverse event pattern.
The compound features a unique mechanism of action through selective nociceptin receptor (search) activation and showed no opioid-like side effects such as somnolence, constipation, or respiratory depression.
Grünenthal plans to initiate a Phase II trial later this year enrolling 400 U.S. patients undergoing bunionectomy, with results expected in the second half of 2027.
Grünenthal announced on June 29, 2026 that it has successfully concluded a Phase I clinical trial evaluating the safety and tolerability of its proprietary nociceptin receptor (search) (NOP) agonist, a novel investigational compound that may represent a first-in-class therapy for acute and chronic pain. The trial, which enrolled 113 healthy participants, demonstrated that the compound was safe and well tolerated, with no dose-dependent adverse event pattern observed.
The company is now preparing to advance the compound into a Phase II trial, which will enroll approximately 400 U.S.-based patients undergoing bunionectomy—a well-established surgical model for evaluating the efficacy and safety of acute pain treatments. The Phase II study is expected to commence later this year, with results anticipated in the second half of 2027.
A Novel Mechanism of Action
Grünenthal's NOP agonist exerts its effects through selective activation of the nociceptin receptor (search), a distinct target within the opioid receptor family that has garnered significant scientific interest for its analgesic potential without the liabilities associated with traditional opioid receptor activation. This unique mechanism of action differentiates the compound from conventional opioid analgesics.
During the Phase I trial, no adverse events commonly associated with opioids—including somnolence, constipation, or respiratory depression—were observed. Additionally, there were no events suggesting any abuse liability potential, a critical differentiator in a therapeutic landscape still grappling with the consequences of the opioid crisis.
"We are excited about the successful completion of our Phase I clinical trial and double down on our efforts to bring the compound to patients," said Uli Brödl, MD, Chief Scientific Officer at Grünenthal. "With selective nociceptin receptor (search) activation, Grünenthal hopes to introduce a new mechanism of action into the pain treatment landscape and provide patients with a much-needed alternative therapy option."
The Bunionectomy Model and Phase II Plans
The upcoming Phase II trial will utilize the bunionectomy model, which is widely recognized as a validated acute postoperative pain model in clinical research. This surgical procedure allows for controlled assessment of analgesic efficacy and safety, providing a rigorous testing ground for novel pain therapeutics.
The planned enrollment of 400 patients underscores Grünenthal's commitment to generating robust clinical data to support the compound's development. Results from the Phase II trial are expected in the second half of 2027.
Addressing Unmet Needs in Pain Management
The successful completion of the Phase I trial marks an important milestone for Grünenthal, a global leader in pain management headquartered in Aachen, Germany. The company has a long track record of developing innovative pain treatments and is focusing its activities on advancing toward its vision of a "World Free of Pain."
If the NOP agonist continues to demonstrate favorable safety and efficacy profiles in subsequent trials, it could offer a meaningful alternative for patients suffering from acute and chronic pain conditions who currently rely on therapies with significant side effect burdens or abuse potential. The compound's potential to deliver robust pain relief across a broad range of conditions without the drawbacks of opioids positions it as a potentially transformative addition to the pain management armamentarium.